Document is current
Any future updates will be listed below
-
Authors
Dalal, Prarthana J.
Singhal, Rashi
Hu, Boyan
Stark, Drew
Rossiter, Nicholas J.
Jain, Chesta
Sajjakulnukit, Peter
Lyssiotis, Costas A.
Shah, Yatrik M.
-
Funding
Funding for this research was provided by:
National Cancer Institute (T32 CA009357)
National Cancer Institute (R37 CA237421)
National Cancer Institute (R01 CA148828)
University of Michigan Pioneers Fellowship
National Institute of General Medical Sciences (T32 GM145304)
National Institute of General Medical Sciences (T32 GM150581)
Rackham Babour Fellowship
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 4 February 2026
First Online: 12 February 2026
Declarations
:
: Over the past three years, CAL served as a consultant for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures, and T-Knife Therapeutics. He is also an inventor on patents related to KRAS-regulated metabolic pathways, redox control mechanisms in pancreatic cancer, and therapeutic targeting of the GOT1-ME1 pathway (U.S. Patent No. 2015126580-A1, 2015; U.S. Patent No. 20190136238, 2019; and International Patent No. WO2013177426-A2, 2015). The remaining authors declare no competing interests.
: Combined HIF-2α inhibition and cholesterol biosynthesis inhibition using statins reveals a metabolic vulnerability in colorectal cancer that enhances ferroptosis, thus offering a clinically actionable strategy for therapeutic intervention.
: The authors declare no competing interests.
